International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 2 Mar - Apr 2026, pp: 117-125 www.ijprajournal.com ISSN: 2456-4494

Unraveling Long COVID Brain Fog: Biological Mechanisms, Neuroimaging Insights, and Clinical Implications

Author: [1]S. Ahalya, [2]Dr. B.V. Ramana, [3]B. Yoga Amrutha , [4] K.V.S. Naga Vignetha
Student, Doctor of Pharmacy, Dr. K.V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool.
Dr. K.V. Subba Reddy Institute of Pharmacy, Dupadu, Kurnool, Andhra Pradesh, India, 518002

Date of Submission: 05-03-2026 Date of Acceptance: 15-03-2026

ABSTRACT
The global COVID-19 pandemic has left many survivors experiencing persistent neurological and cognitive symptoms collectively known as “brain fog,” a prominent feature of Long COVID. Brain fog is characterized by impaired attention, memory difficulties, reduced executive function, mental fatigue, sleep disturbances, and emotional instability. These symptoms can significantly disrupt daily activities, occupational performance, and overall quality of life, even in individuals who initially had mild acute infections.Although the exact mechanisms underlying Long COVID brain fog remain unclear, current evidence suggests a multifactorial pathophysiology. Neuroinflammation appears to play a central role, with prolonged immune activation leading to inflammatory changes in the brain that interfere with normal neuronal signaling. Elevated cytokines and ongoing immune responses may contribute to cognitive dysfunction and persistent fatigue.Endothelial dysfunction and microvascular injury are also considered important contributors. Damage to the vascular endothelium can impair cerebral blood flow and oxygen delivery, resulting in subtle yet clinically meaningful cognitive deficits. Microclot formation and vascular inflammation may further compromise brain function. In addition, dysregulation of the immune system and autonomic nervous system may explain the combination of cognitive, cardiovascular, and systemic symptoms observed in many patients.Neuroimaging studies provide supportive evidence for these mechanisms. Structural and functional brain changes have been observed, particularly in the frontal, parietal, and limbic regionsareas responsible for attention, memory, executive function, and emotional regulation. Altered connectivity and reduced gray matter volume in these regions may underlie the persistent cognitive and psychological symptoms reported by patients.Overall, Long COVID brain fog represents a complex and multifaceted condition involving inflammatory, vascular, immune, and neurological pathways. A comprehensive understanding of these mechanisms is crucial for improving diagnostic strategies and developing targeted therapeutic interventions to enhance recovery and long-term outcomes for affected individuals.

Keywords: Brain fog, long COVID, SARS-COV-2, Cognitive impairment, Neuroimaging, Blood Brain Barrier, Neuroinflammation.

I. INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has profoundly impacted global health. While acute infection primarily targets the respiratory system, it is now evident that COVID-19 exerts multi-systemic effects, including lasting neurological sequelae. A subset of individuals who recover from the acute infection continue to experience persistent symptoms lasting weeks to months, a condition collectively termed **Long COVID** or **post-acute sequelae of SARS-CoV-2 infection (PASC)**. Among these manifestations, “brain fog” is one of the most debilitating, characterized by difficulties in attention, processing speed, memory, and executive function.

Recent data suggest that **20–35%** of COVID-19 survivors experience measurable cognitive deficits up to one year after infection. These symptoms occur independently of disease severity; even individuals with mild or asymptomatic infections may experience prolonged neurocognitive issues. Brain fog significantly affects quality of life, work productivity, and psychological well-being, emphasizing its emerging public health relevance.

From a clinical standpoint, brain fog presents as a constellation of symptoms — confusion, forgetfulness, poor concentration, and slowed thinking — that resemble post-viral fatigue

International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 2 Mar - Apr 2026, pp: 117-125 www.ijprajournal.com ISSN: 2456-4494

syndromes observed in other infections such as Epstein–Barr virus and influenza. However, SARS-CoV-2 appears to have unique neurotropic and vascular properties, suggesting that COVID-19–related brain fog may involve distinct neuropathological processes.

The mechanisms underlying Long COVID brain fog are complex and likely multifactorial. Hypotheses include direct viral invasion of the central nervous system (CNS), immune-mediated neuroinflammation, disruption of the blood–brain barrier (BBB), endothelial dysfunction, and mitochondrial dysregulation. Moreover, neuroimaging findings such as gray matter loss in the orbitofrontal cortex, microstructural white matter changes, and altered functional connectivity have provided compelling insights into potential mechanisms.

II. BIOLOGICAL MECHANISMS OF LONG COVID BRAIN FOG

The underlying biology of Long COVID brain fog is complex and multifactorial, reflecting the interplay between direct viral effects, immune activation, endothelial injury, and secondary metabolic disturbances. The following mechanisms have been most consistently implicated.

2.1 Neuroinflammation and Microglial Activation

Persistent neuroinflammation is among the most prominent hypotheses explaining Long COVID brain fog. SARS-CoV-2 infection triggers a robust systemic immune response, resulting in elevated cytokines such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). These cytokines can cross the **blood–brain barrier (BBB)** or activate endothelial and glial cells, initiating neuroinflammatory cascades.

Microglial cells, the brain's resident immune cells, become chronically activated in response to this immune dysregulation. Studies using positron emission tomography (PET) have shown increased microglial activation in the cingulate cortex and hippocampus of post-COVID individuals, correlating with cognitive decline. The sustained release of neurotoxic mediators — nitric oxide, reactive oxygen species (ROS), and cytokines — contributes to synaptic dysfunction and neuronal injury.

2.2 Endothelial Dysfunction and Microvascular Injury

Endothelial injury represents a critical link between systemic infection and cerebral dysfunction. SARS-CoV-2 infects endothelial cells via the **ACE2 receptor**, leading to endotheliitis and microthrombi formation.Autopsy and imaging studies have shown widespread **microvascular damage** in the brain, including perivascular inflammation and fibrin deposition.

Microvascular compromise impairs oxygen and nutrient delivery, leading to localized ischemia and white matter disruption. These processes are particularly pronounced in the frontal and temporal lobes, regions associated with attention and memory. Elevated plasma markers such as **von Willebrand factor** and **D-dimer** in Long COVID patients further support ongoing vascular pathology.

2.3 Hypoxia and Mitochondrial Dysfunction

During acute COVID-19, systemic hypoxia resulting from respiratory compromise can induce neuronal energy deficits. However, even after recovery, mitochondrial dysfunction may persist. SARS-CoV-2 can disrupt mitochondrial dynamics, promoting oxidative stress and impairing adenosine triphosphate (ATP) synthesis.

This bioenergetic imbalance affects high-energy neurSSSonal populations, particularly in the hippocampus and prefrontal cortex. In vitro studies suggest that viral proteins such as **ORF9b** localize to mitochondria, inhibiting antiviral signaling pathways and exacerbating oxidative stress. Such mitochondrial disturbances may contribute to fatigue, memory impairment, and executive dysfunction — hallmarks of Long COVID brain fog.

(Table 1. Summary of biological mechanisms and their cognitive outcomes.)

1. Mechanism	2. Key Pathways	3. Cognitive Effects
4. Neuroinflammation	5. Cytokine storm, microglial activation	6. Attention & memory deficits
7. Endothelial dysfunction	8. Microthrombi, BBB disruption	9. Processing speed, fatigue
10. Hypoxia & mitochondrial injury	11. Oxidative stress, ATP depletion	12. Executive dysfunction

International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 2 Mar - Apr 2026, pp: 117-125 www.ijprajournal.com ISSN: 2456-4494

13. Autonomic imbalance	14. Dysregulated sympathetic tone	15. Brain fog, dizziness

2.4 Blood–Brain Barrier (BBB) Disruption

The BBB serves as a critical interface between systemic circulation and the CNS. During SARS-CoV-2 infection, pro-inflammatory cytokines and endothelial injury compromise BBB integrity. Studies using MRI contrast and cerebrospinal fluid (CSF) analysis have revealed increased BBB permeability markers, such as albumin quotient and S100B protein.

This disruption allows peripheral immune mediators, autoantibodies, and viral remnants to enter the CNS, sustaining inflammation even after viral clearance. Persistent BBB leakage may explain the chronic nature of brain fog, as neuroinflammation and immune activation perpetuate a cycle of neuronal dysfunction and glial reactivity.

2.5 Autonomic Nervous System Dysregulation

Many patients with Long COVID report dizziness, palpitations, and “brain fog” consistent with **dysautonomia**, including postural orthostatic tachycardia syndrome (POTS). Autonomic imbalance — heightened sympathetic activity with reduced parasympathetic tone — impairs cerebral autoregulation and leads to reduced cortical perfusion.

Functional MRI studies show altered connectivity within the **insula**, **brainstem**, and **prefrontal cortex**, areas governing autonomic control and interoception. Dysautonomia thus represents both a cause and consequence of the broader neuroinflammatory process.

III. NEUROIMAGING INSIGHTS INTO LONG COVID BRAIN FOG

Advancements in neuroimaging have provided crucial insights into the structural and functional brain changes underlying Long COVID brain fog. Imaging studies have revealed alterations across multiple modalities — including **magnetic resonance imaging (MRI)**, **positron emission tomography (PET)**, and **diffusion tensor imaging (DTI)** — that correlate with cognitive and neuropsychiatric symptoms.

3.1 Structural MRI Findings

Magnetic resonance imaging (MRI) studies have demonstrated measurable gray and white matter changes in individuals recovering from COVID-19. A landmark study from the UK Biobank cohort compared pre- and post-infection scans and found significant reductions in **gray matter thickness** within the **orbitofrontal cortex**, **parahippocampal gyrus**, and **superior temporal regions**. These findings align with clinical reports of memory and executive dysfunction.

Volumetric MRI has further revealed **cortical atrophy** and **ventricular enlargement**, consistent with global neuroinflammatory processes. White matter hyperintensities (WMHs), indicative of microvascular injury, have also been frequently reported, particularly in frontal subcortical regions.

3.2 Diffusion Tensor Imaging (DTI) and Microstructural Changes

DTI provides a sensitive measure of white matter microstructure. Several studies have identified reduced **fractional anisotropy (FA)** and increased **mean diffusivity (MD)** in Long COVID patients, particularly in the **corpus callosum**, **cingulum bundle**, and **superior longitudinal fasciculus**.

These alterations suggest demyelination or axonal injury secondary to inflammation or hypoxic-ischemic injury. Importantly, DTI abnormalities correlate with decreased cognitive test scores, supporting their relevance to clinical brain fog symptoms.

3.3 Functional MRI (fMRI) Studies

Functional MRI studies have highlighted widespread disruptions in brain network connectivity. Resting-state fMRI analyses reveal reduced **functional connectivity** within the **default mode network (DMN)** — particularly between the **posterior cingulate cortex** and **medial prefrontal cortex**. This pattern mirrors findings in other fatigue-related disorders such as chronic fatigue syndrome and multiple sclerosis.

Task-based fMRI has demonstrated **hypoactivation** of the **dorsolateral prefrontal cortex (DLPFC)** during working memory tasks, and **hyperactivation** of compensatory regions in the parietal cortex, suggesting inefficient cognitive processing.

3.4 PET and Molecular Imaging Findings

PET imaging provides metabolic and neuroinflammatory perspectives on Long COVID brain fog. Studies using **[18F]-FDG PET** have

International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 2 Mar - Apr 2026, pp: 117-125 www.ijprajournal.com ISSN: 2456-4494

identified **hypometabolism** in the **frontal lobes**, **temporal cortices**, and **brainstem**, correlating with fatigue and concentration deficits.

Additionally, PET tracers targeting **translocator protein (TSPO)** have revealed **microglial activation**, particularly in the **cingulate cortex** and **thalamus**, suggesting persistent neuroinflammation. These findings support the hypothesis that ongoing immune activation contributes to cognitive symptoms long after viral clearance.

(Table 2. Summary of neuroimaging findings in Long COVID brain fog.)

Imaging Modality	Key Findings	Brain Regions	Clinical Correlation
MRI	Gray matter loss	Orbitofrontal, hippocampal	Memory,attention deficits
DTI	ReducedFA,increased MD	Corpus callosum, cingulum	Processingspeed, executive function
fMRI	DecreasedDMN connectivity	PCC, DLPFC	Fatigue,cognitive inefficiency
PET	Hypometabolism, microglial activation	Frontal, temporal, brainstem	Cognitive fatigue, brain fog

3.5 Advanced Imaging and Emerging Techniques

Emerging modalities such as **magnetic resonance spectroscopy (MRS)** and **arterial spin labeling (ASL)** provide additional perspectives on metabolic and perfusion abnormalities. MRS studies have detected reduced **N-acetylaspartate (NAA)** levels — a neuronal integrity marker — and increased **choline** and **myo-inositol**, consistent with gliosis and inflammation.

ASL has revealed altered **cerebral blood flow (CBF)** patterns, particularly hypoperfusion in the **frontal and parietal lobes**, supporting the theory of microvascular dysfunction

IV. CLINICAL IMPLICATIONS AND MANAGEMENT STRATEGIES

Understanding the clinical relevance of Long COVID brain fog requires integrating neurobiological insights with patient-centered approaches. Cognitive dysfunction in post-COVID individuals has far-reaching consequences, affecting daily functioning, occupational performance, and overall quality of life. The challenge lies in accurately diagnosing, monitoring, and managing these symptoms amid limited standardized guidelines.

4.1 Clinical Presentation and Diagnosis

Brain fog in Long COVID manifests as a constellation of cognitive symptoms—impaired concentration, slowed thinking, poor working memory, and difficulty multitasking. These symptoms often fluctuate and coexist with fatigue, anxiety, and sleep disturbances.

Neurological examination findings are usually subtle, and conventional imaging may appear normal despite significant cognitive complaints. Therefore, clinicians must rely on **neuropsychological assessment tools** and symptom inventories such as:

- **Montreal Cognitive Assessment (MoCA)**
- **Trail Making Test (TMT)**
- **Digit Symbol Substitution Test (DSST)**
- **Cognitive Failures Questionnaire (CFQ)**.

Biomarkers, though not yet standardized, are under investigation. Elevated **neurofilament light chain (NfL)**, **glial fibrillary acidic protein (GFAP)**, and inflammatory markers (IL-6, CRP) have been associated with persistent cognitive impairment.

4.2 Differential Diagnosis

Clinicians must distinguish Long COVID brain fog from overlapping conditions, including **depression, anxiety disorders, post-intensive care syndrome (PICS)**, and **myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)**. Careful history-taking, cognitive screening, and exclusion of secondary causes—such as thyroid dysfunction or vitamin deficiencies—are essential.

International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 2 Mar - Apr 2026, pp: 117-125 www.ijprajournal.com ISSN: 2456-4494

(Table 3. Differential diagnosis of cognitive dysfunction in Long COVID.)

Condition	Key Features	Differentiating Factors	Diagnostic Approach
LongCOVID brain fog	Attention,memory, processing deficits	OnsetafterSARS-CoV-2 infection	MoCA,fMRI, biomarkers
Depression	Poor concentration, fatigue	Low mood predominates	PHQ-9,clinical interview
ME/CFS	Post-exertional malaise	Often pre-existing fatigue disorders	Physicalactivity intolerance
PICS	After ICU stay, hypoxia	Associated with critical illness	Medicalhistory review

4.3 Therapeutic Approaches

Currently, no specific pharmacologic treatment exists for Long COVID brain fog. Management focuses on **symptomatic relief**, **neurorehabilitation**, and **multidisciplinary care**.

4.3.1 Cognitive Rehabilitation

Cognitive rehabilitation forms the cornerstone of management. Structured programs emphasizing **attention retraining**, **working memory exercises**, and **executive function practice** have demonstrated improvement in daily performance. Digital tools and virtual cognitive therapy platforms can extend access to home-based rehabilitation.

4.3.2 Pharmacologic Interventions

Pharmacotherapy remains exploratory. Small studies suggest potential benefits of **modafinil**, **methylphenidate**, and **amantadine** in alleviating fatigue and cognitive slowing, though robust randomized trialsarelacking.

Anti-inflammatory and neuroprotective agents such as **omega-3 fatty acids**, **N-acetylcysteine (NAC)**, and **low-dose naltrexone (LDN)** are under investigation for their ability to modulate neuroinflammatory pathways.

(Table 4. Summary of pharmacologic interventions under investigation.)

Drug/Class	Mechanism	Evidence Level	Reported Benefit
Modafinil	Dopaminergic stimulant	Pilot studies	Improved alertness
N-acetylcysteine	Antioxidant, glutathione precursor	Observational	Reduced fatigue
Low-dose naltrexone	Microglial modulator	Early trials	Improved cognition
Omega-3 fatty acids	Anti-inflammatory	Case series	Cognitive clarity

4.3.3 Lifestyle and Supportive Measures

Lifestyle interventions play a crucial role. Regular **aerobic exercise**, **adequate sleep hygiene**, **hydration**, and **balanced nutrition** support neuroplasticity and vascular health.

Psychological counseling and **cognitive behavioral therapy (CBT)** can alleviate associated anxiety and depression, thereby improving cognitive performance.

4.4 Prognosis and Recovery

Recovery trajectories vary widely. Longitudinal studies suggest that **40–60%** of patients experience gradual improvement over 6–12 months, while a subset report persistent symptoms beyond one year .
Factors associated with delayed recovery include **older age**, **female sex**, **pre-existing psychiatric conditions**, and **severe acute infection**.

Ongoing follow-up with cognitive assessments and supportive therapy remains essential. Early intervention and rehabilitation are associated with better functional outcomes, reinforcing the importance of multidisciplinary management.

V. FUTURE DIRECTIONS AND RESEARCH GAPS

Despite major advances in understanding Long COVID brain fog, significant uncertainties remain regarding its precise biological origins, diagnostic markers, and optimal treatment strategies. Future research must bridge clinical observations with molecular and imaging insights to develop standardized, evidence-based care.

5.1 Need for Standardized Diagnostic Criteria

Current diagnostic approaches rely on subjective symptom reports and non-specific cognitive tests. A **unified diagnostic framework** incorporating neuroimaging biomarkers, inflammatory markers, and cognitive performance scores is urgently needed [63].'

Future guidelines should emphasize:

- Objective diagnostic thresholds (e.g., MoCA cutoffs specific to Long COVID).
- Integration of fMRI, PET, and DTI biomarkers for early detection.
- Development of **"Long COVID Cognitive Severity Index"** for clinical use.

5.2 Longitudinal and Multi-Omics Studies

Understanding the persistence of cognitive dysfunction requires **longitudinal, multi-center cohort studies**.
Future studies should focus on:

- **Time-course mapping** of cognitive recovery using serial neuroimaging and neuropsychological evaluations.
- **Multi-omics profiling** (genomics, proteomics, metabolomics) to identify biomarkers predicting cognitive resilience or vulnerability.
- Investigating the impact of **viral persistence** and **immune dysregulation** over time.

Focus Area	Methodology	Expected Outcome
Transcriptomic analysis	RNA sequencing	Identify genes linked to neuroinflammation
Proteomic profiling	LC-MS/MS	Detect plasma markers of neural injury
Metabolomics	NMR spectroscopy	Explore metabolic signatures of brain fatigue
Longitudinal MRI	Serial imaging	Track structural brain recovery

5.3 Therapeutic Innovation

Current management remains largely supportive. The next phase of research should explore **targeted neurotherapeutic strategies**, including:

- **Neuroprotective drugs** (e.g., minocycline, melatonin analogs).
- **Anti-inflammatory therapies** targeting microglial activation.
- **Neuromodulation techniques** such as **transcranial magnetic stimulation (TMS)** or **transcranial direct current stimulation (tDCS)** to enhance cognitive recovery [65,66].
- **Personalized rehabilitation protocols** based on neuroimaging profiles.

5.4 Global Collaboration and Data Sharing

Given the global scale of Long COVID, **international data registries** and **neuro-COVID consortia** are critical. Collaborative databases integrating neuroimaging, clinical, and biomarker data will enable meta-analyses to identify consistent neural signatures.

Equitable representation of low- and middle-income countries is essential to capture diverse genetic and environmental contexts influencing recovery outcomes.

5.5 Ethical and Societal Considerations

As neuroimaging and AI-driven cognitive diagnostics evolve, ethical frameworks must address issues of **data privacy**, **stigma**, and **healthcare accessibility**.

Policies ensuring affordable cognitive rehabilitation and inclusion of Long COVID patients in workforce reintegration programs are vital.

5.6 Future Vision

The ultimate goal is to transition from descriptive understanding to **precision medicine** in Long COVID care—where biological, imaging, and psychological data inform individualized treatment.

Emerging technologies like **AI-based cognitive analytics** and **wearable neuro-sensors** may soon enable continuous cognitive monitoring, facilitating early intervention and improved outcomes.

VI. CONCLUSION

Long COVID brain fog represents a multifactorial neurological syndrome arising from the complex interplay of neuroinflammation, vascular dysfunction, and immune-mediated injury. The accumulating evidence from neuroimaging, molecular biology, and clinical studies supports a model of **persistent neuroimmune activation** and **disrupted brain network connectivity**, leading to cognitive fatigue and executive dysfunction.

Structural MRI, DTI, and PET imaging have revealed both anatomical and metabolic changes, particularly in the **frontal**, **temporal**, and **limbic** regions. These findings bridge the gap between patient-reported symptoms and measurable neural alterations. However, diagnostic ambiguity, heterogeneous symptom profiles, and

International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 2 Mar - Apr 2026, pp: 117-125 www.ijprajournal.com ISSN: 2456-4494

lack of standardized biomarkers continue to limit effective management.

Clinically, management should be **multidisciplinary**, combining cognitive rehabilitation, psychological support, and targeted pharmacological interventions. Anti-inflammatory and neuromodulatory therapies show early promise but require validation through large-scale, controlled trials.

Future research must prioritize **standardized diagnostic criteria**, **multi-omics profiling**, and **longitudinal neuroimaging** to establish mechanistic clarity. Integrating artificial intelligence for pattern recognition and prognosis could transform patient care.

Ultimately, unraveling the biological and neuroimaging mechanisms of Long COVID brain fog will not only advance our understanding of post-viral neurocognitive syndromes but also pave the way toward **precision neurorehabilitation** and improved quality of life for millions affected worldwide.

REFERENCES

[1]. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27(4):601–15.

[2]. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416–27.

[3]. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697–707.

[4]. Cataldo SA, et al. Cognitive impact and brain structural changes in long COVID: a systematic review. BMC Neurol. 2024; Available from: PMC11572126.

[5]. Turner S, Khan MB, Németh G, et al. Long COVID: pathophysiological factors and abnormalities of immune and vascular systems — implications for brain function. Frontiers (review). 2023; (review). [PMCID: PMC10113134]

[6]. VanElzakker MB, Brumfield SA, Hensen C, et al. Neuroinflammation in post-acute sequelae of COVID-19: PET evidence of increased microglial activation. J Neuroimmunol. 2024; [PMCID: PMC11225883].

[7]. Kell DB, Laubscher GJ, Pretorius E. Fibrinaloid microclots in long COVID: assessing clinical relevance and detection methods. Thromb J. 2024; Available from: PMC11491705.

[8]. Kesler SR, et al. Altered functional brain connectivity, efficiency, and cognition in adults with prior COVID-19. Sci Rep. 2024;14:xxxx.

[9]. Talkington GMG, et al. Neurological sequelae of long COVID: clinical and imaging synthesis. Front Neurol. 2025; (review).

[10]. Toepffer A, et al. Cognition-associated gray matter volume alterations in long COVID: longitudinal cohort evidence. NeuroImage Clin. 2025; (open access).

[11]. Taquet M, Luciano S, Geddes JR, Harrison PJ. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19. Nat Med. 2023;29:xxxx–xxxx.

[12]. Van der Knaap N, et al. Advanced neuroimaging in COVID-19: methods and potential biomarkers. Front Neurol. 2024; (review).

[13]. Cárdenas-Rodríguez N, et al. Post-COVID condition and neuroinflammation: oxidative stress and blood-brain barrier implications. Antioxidants (Basel). 2025;14(7):840.

[14]. Abramoff B, Dillingham T, Brown LA, et al. Long COVID study points to potential cause for "brain fog" — serotonin and interferon pathway disruptions. Stat News. 2023 Oct. (news/analysis of primary study).

[15]. UK Biobank. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. UK Biobank publication page. 2022. (dataset/summary of Douaud et al.)

[16]. Nelson BK, et al. Quantitative brain volume differences between COVID-19 cohorts and controls: a multi-study meta-analysis. Hum Brain Mapp. 2025; (in press).

[17]. Brambilla M, et al. Low-grade inflammation and platelet activation in long COVID syndrome. J Inflamm Res. 2025; (review).

[18]. Rasouli R, et al. Low-intensity ultrasound lysis of amyloid microclots: lab models

International Journal of Pharmaceutical Research and Applications
Volume 11, Issue 2 Mar - Apr 2026, pp: 117-125 www.ijprajournal.com ISSN: 2456-4494

and implications for long COVID. Front Bioeng Biotechnol. 2025;13:1604447.
[19]. Amiruddin R, et al. Brain FDG-PET imaging in long COVID patients: metabolic alterations as potential biomarkers. J Nucl Med. 2024;65(Suppl 2):242351.
[20]. VanElzakker MB. Neuroinflammation in post-acute sequelae of COVID-19: PET and molecular imaging evidence. NeuroImage Clin. 2024; (review).
[21]. Mohammadi-Nejad AR, et al. Accelerated brain ageing during the COVID-19 pandemic: longitudinal UK Biobank analysis. Nat Commun. 2025; (article).
[22]. Hodes RJ, et al. Imaging and cognitive changes in patients with long COVID compared with recovered controls: a multicenter study. NeuroImage Clin. 2024/25; (manuscript).
[23]. Kesler SR, et al. Functional connectivity and cognitive performance after COVID-19: an MRI study. Sci Rep. 2024;14:xxxx.
[24]. Wood GK, et al. Posthospitalization COVID-19 cognitive deficits at 1 year and brain injury markers. Nat Med. 2025; (article).
[25]. Montani D, et al. Post-acute COVID-19 syndrome: organ systems and long-term follow-up. Clin Microbiol Infect. 2022; (review). [PMCID: PMC8924706]
[26]. Schou TM, Joca S, Winther G, et al. Psychiatric and neuropsychiatric sequelae of COVID-19: systematic review. Lancet Psychiatry. 2021;8(2):121–34.
[27]. Taquet M, et al. Cognitive and psychiatric symptom trajectories 2–3 years after SARS-CoV-2 infection. Lancet Psychiatry. 2024; (longitudinal cohort).
[28]. Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 infection: a systematic review and meta-analysis. Nat Med. 2022;28: 429–40.
[29]. Knapp SAB, et al. Neurocognitive and psychiatric outcomes associated with COVID-19: meta-analysis. J Neurol Neurosurg Psychiatry. 2024;95:1207–.
[30]. Hampshire A, et al. Cognition and memory after COVID-19 in a large population study. N Engl J Med. 2024; (article).
[31]. Kumar PR, et al. Brain disorders: Impact of mild SARS-CoV-2 infection on brain structure and function. Brain Behav. 2023; (review).
[32]. Stehouwer CD, et al. Strategies for mitigating the neurologic impact of long COVID: pharmacologic and rehabilitative approaches. US Pharm. 2023;48(11):1–9.
[33]. O'Mahoney L, et al. Intervention modalities for brain fog caused by long COVID: systematic review of the literature. Neurol Sci. 2024;45:2951–68.
[34]. Pretorius E, Laubscher GJ, Kell DB. Microclots and platelet hyperactivation in acute and long COVID: a review of evidence and detection approaches. J Clin Med. 2022/2023; (review).
[35]. Laubscher GJ, et al. Fibrin amyloid microclot formation in long COVID patients: clinical observations and laboratory detection. Thromb Res. 2023; (paper).
[36]. Kruger K, et al. Microvascular abnormalities and cognitive complaints in long COVID: multimodal imaging study. J Cereb Blood Flow Metab. 2024; (article).
[37]. Cardenas-Rodriguez N, et al. Oxidative stress and neuroinflammation in post-COVID condition: implications for cognitive dysfunction. Antioxidants. 2025;14:840.
[38]. Toepffer A, et al. Cognition-associated gray matter volume alterations in long COVID: longitudinal cohort evidence. NeuroImage Clin. 2025; (PMCID: PMC12536713).
[39]. VanElzakker MB, et al. PET evidence of persistent neuroinflammation in PASC cohorts. J Nucl Med. 2024; (article).
[40]. Kesler SR, et al. Altered functional connectivity and efficiency in cognitive networks after COVID-19. Sci Rep. 2024;14:xxxx.
[41]. Carreras-Vidal L, et al. Functional brain abnormalities in post-COVID condition: an fMRI study. Sci Rep. 2025; (article).
[42]. Stebbing J, et al. Molecular pathways linking inflammation, mitochondrial dysfunction and neurocognitive decline in Long COVID. Signal Transduct Target Ther. 2023;8:340.
[43]. Li J, et al. Long-term health outcomes and pathophysiology of long COVID: comprehensive review. Signal Transduct Target Ther. 2023;8: (review).

[44]. Montani D, et al. Post-acute COVID-19 syndrome: comprehensive clinical guidance. Chest. 2021;160(1):199–215.
[45]. Hampshire A, et al. Cognitive sequelae after SARS-CoV-2 infection: population-based large cohort study. NEJM. 2024; (article).
[46]. Cardenas-Rodriguez N, et al. Biomarkers of BBB disruption in long COVID with cognitive complaints. Neurol Sci. 2024; (study).
[47]. Wood GK, et al. Persistent cognitive impairment and structural changes at 12 months after hospitalization for COVID-19. Nat Med. 2025; (article).
[48]. Rasouli R, et al. Detection of long COVID microclots using pulsed speckle contrast optical spectroscopy: preclinical validation. bioRxiv. 2025; (preprint).
[49]. Laubscher GJ, et al. Pilot interventional trials targeting microclots in long COVID (case series). Thromb Res. 2024; (report).
[50]. National Institute for Health and Care Excellence (NICE). Managing the long-term effects of COVID-19. NICE guideline [NG188]. 2024 update.
[51]. WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus, 2021. WHO. 2021.
[52]. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.
[53]. Blomberg B, et al. Long COVID in a prospective cohort of home-isolated patients: outcomes and risk factors. Nat Commun. 2021;12: (article).
[54]. de Erausquin GA, et al. The neurological impact of COVID-19: short- and long-term consequences. BMJ Neurol Open. 2023; (review).
[55]. O'Mahoney L, et al. Cognitive rehabilitation feasibility trials for long COVID: pilot RCT results. Clin Rehabil. 2024; (pilot).
[56]. Gopinath K, et al. Use of modafinil for cognitive fatigue in post-COVID syndrome: pilot study. J Psychopharmacol. 2023; (pilot).
[57]. Heddy S, et al. N-acetylcysteine and mitochondrial support in post-viral cognitive dysfunction: preliminary data. Mitochondrion. 2024; (study).
[58]. Kim Y, et al. Transcranial magnetic stimulation as adjunct in post-COVID cognitive rehabilitation: early trials. Brain Stimul. 2024; (trial).
[59]. WHO Technical Brief: Long COVID: research priorities. 2023.
[60]. National Institutes of Health (NIH) RECOVER Initiative: study design and early reports. 2024.
[61]. Taquet M, et al. Longitudinal cognitive and psychiatric trajectories 2–3 years after infection. Lancet Psychiatry. 2024; (article).
[62]. Xiong Q, et al. Follow-up of recovered COVID-19 patients: persistent symptoms and impact on quality of life. Int J Infect Dis. 2021; (cohort).
[63]. Parker AM, et al. Addressing the post-acute sequelae of SARS-CoV-2 infection. Lancet Respir Med. 2021;9:1376–9.
[64]. Kruger K, et al. Microvascular perfusion deficits in long COVID: ASL MRI study. J Cereb Blood Flow Metab. 2024; (article).
[65]. Sun Z, et al. TSPO PET imaging of microglial activation in post-COVID condition. J Nucl Med. 2024; (study).
[66]. International Consensus Conference on Long COVID Research Priorities. 2024.
[67]. Global NeuroCOVID Consortium: data sharing and imaging harmonization statement. 2024.
[68]. WHO Rehabilitation Toolkit for Long COVID. 2024.
[69]. Pilotto A, et al. Brain inflammation and cognitive impairment following COVID-19: neuropathological correlates. Acta Neuropathol. 2023; (article).
[70]. Kuehnel MP, et al. Blood-based biomarkers and cognitive outcomes after SARS-CoV-2 infection: prospective cohort. Alzheimers Res Ther. 2024; (study).